Migdal Insurance & Financial Holdings’s UroGen Pharma URGN Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.4M	Hold	770,909	–	–	0.18%	69
2026 Q1	$13.9M	Hold	770,909	–	–	0.12%	82
2025 Q4	$18.1M	Hold	770,909	–	–	0.16%	70
2025 Q3	$15.4M	Hold	770,909	–	–	0.17%	70
2025 Q2	$10.6M	Sell	770,909 -15,563	-2%	-$149K	0.13%	84
2025 Q1	$8.7M	Buy	786,472 +100,000	+15%	+$1.07M	0.12%	91
2024 Q4	$7.31M	Hold	686,472	–	–	0.1%	87
2024 Q3	$8.72M	Hold	686,472	–	–	0.14%	72
2024 Q2	$11.5M	Hold	686,472	–	–	0.19%	74
2024 Q1	$10.3M	Buy	686,472 +38,170	+6%	+$624K	0.16%	78
2023 Q4	$9.72M	Hold	648,302	–	–	0.2%	76
2023 Q3	$9.08M	Sell	648,302 -50,000	-7%	-$803K	0.19%	74
2023 Q2	$7.23M	Hold	698,302	–	–	0.17%	77
2023 Q1	$6.45M	Hold	698,302	–	–	0.14%	74
2022 Q4	$6.19M	Hold	698,302	–	–	0.14%	72
2022 Q3	$5.81M	Hold	698,302	–	–	0.13%	79
2022 Q2	$5.72M	Hold	698,302	–	–	0.13%	76
2022 Q1	$6.08M	Hold	698,302	–	–	0.11%	93
2021 Q4	$6.64M	Hold	698,302	–	–	0.06%	123
2021 Q3	$11.7M	Hold	698,302	–	–	0.12%	110
2021 Q2	$10.7M	Hold	698,302	–	–	0.11%	118
2021 Q1	$13.6M	Sell	698,302 -40,000	-5%	-$849K	0.14%	122
2020 Q4	$13.3M	Hold	738,302	–	–	0.16%	97
2020 Q3	$14.2M	Hold	738,302	–	–	0.2%	100
2020 Q2	$19.3M	Hold	738,302	–	–	0.31%	71
2020 Q1	$13.2M	Hold	738,302	–	–	0.31%	67
2019 Q4	$24.6M	Sell	738,302 -35,000	-5%	-$955K	0.47%	49
2019 Q3	$18.4M	Buy	773,302 +420,000	+119%	+$13.7M	0.38%	63
2019 Q2	$12.7M	Hold	353,302	–	–	0.32%	64
2019 Q1	$13.1M	Buy	+353,302	New	+$14.8M	0.31%	63

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Migdal Insurance & Financial Holdings's URGN Position: Q2 2026 in Review

Migdal Insurance & Financial Holdings held its UroGen Pharma (URGN) position steady in Q2 2026 at 770,909 shares worth $28.4M. The position accounts for 0.18% of the portfolio, ranked #69.

Migdal Insurance & Financial Holdings first reported a position in URGN in Q1 2019 and has held it in 30 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Migdal Insurance & Financial Holdings held 770,909 shares of UroGen Pharma worth $28.4M as of Q2 2026.
Migdal Insurance & Financial Holdings left its UroGen Pharma share count unchanged in Q2 2026.
UroGen Pharma made up 0.18% of Migdal Insurance & Financial Holdings's portfolio in Q2 2026, its #69 holding.
Migdal Insurance & Financial Holdings first reported a position in UroGen Pharma in Q1 2019 and has held it in 30 quarters since.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q2 2026, filed 10 Aug 2026.